Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment
modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently …

Despite a prevailing dogma wherein antibody drug conjugates (ADCs) increase the
maximum tolerated dose of potent cytotoxin payloads while lowering the minimum effective …

Despite significant advances in the treatment of cervical, ovarian, and uterine cancers with
the approvals of checkpoint and PARP inhibitors into standard treatment, patients with …

Introduction: We discuss chemical conjugation strategies for antibody-drug conjugates
(ADCs) from an industrial perspective and compare three promising chemical conjugation …

In the past two decades, antibody–drug conjugates have gained increasing attention
because they expand the therapeutic index when compared with that of traditional …

HER2-targeted therapies for patients with HER2+ breast cancer are rapidly evolving,
offering a range of more complex and personalized treatment options. Currently, an array of …

Antibody–drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has
successfully reached patient treatment in different clinical scenarios. ADCs are formed by an …

The present article reviews the current evidence for antibody-drug conjugates (ADCs) in
gynecologic cancer. ADCs consist of a highly selective monoclonal antibody for a tumor …

Introduction Mirvetuximab soravtansine (mirvetuximab) is an antibody drug conjugate (ADC)
comprised of a humanized folate receptor alpha (FRα)-binding monoclonal antibody …